Favezelimab plus pembrolizumab for anti–PD-1–refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

Blood Neoplasia · Elsevier

Аннотация

Publication date: November 2026 Source: Blood Neoplasia, Volume 3, Issue 4 Author(s): John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Читать у издателя →

Похожие статьи